-
Je něco špatně v tomto záznamu ?
The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients
E. Girmanova, J. Duskova, P. Mrazova, M. Fialova, O. Viklicky, P. Hruba
Status minimální Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
PubMed Central
od 2020
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- COVID-19 * imunologie prevence a kontrola MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- protilátky virové krev MeSH
- SARS-CoV-2 imunologie MeSH
- senioři MeSH
- T-lymfocyty * imunologie MeSH
- transplantace ledvin * škodlivé účinky MeSH
- vakcinace metody MeSH
- vakcíny proti COVID-19 * imunologie aplikace a dávkování MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFN?+TNF?+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels. Key words: mRNA COVID-19 vaccine, T cells, SARS-CoV-2 antibodies, Kidney transplantation, mRNA vaccination.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017599
- 003
- CZ-PrNML
- 005
- 20250312151318.0
- 007
- ta
- 008
- 241004s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.935318 $2 doi
- 035 __
- $a (PubMed)39264085
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Girmanova, E $u Transplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. petra.hruba@ikem.cz
- 245 14
- $a The Impact of COVID-19 Third Dose Vaccination on the Magnitude of Antigen Specific T Cells in Kidney Transplant Patients / $c E. Girmanova, J. Duskova, P. Mrazova, M. Fialova, O. Viklicky, P. Hruba
- 520 9_
- $a Measuring T cell response can add information about antivirus immunity provided by antibody test results. The study evaluates the impact of a third mRNA COVID-19 vaccine dose on T cell response and antibody production in kidney transplant recipients (25 KTRs) versus healthy controls (26 Hc). Results show a significant rise in S-activated CD4+CD154+IFN?+TNF?+ double producer cells in both KTRs (p=0.025) and Hc (p=0.009) as well as increased spike antibody response in KTRs (p=0.00019) and Hc (p=3.10-8) third-month post-third dose. Moreover, the study revealed a drop in seronegative KTRs (non-responders) from 9/25 (36%) pre-third dose to 2/25 (7%) at 3 months post-third dose while 5/9 (56%) of non-responders post-second dose showed specific T cell responses. Notably, the third dose significantly improved seroconversion rates in both KTRs and Hc, although Hc individuals exhibited higher antibody levels. Key words: mRNA COVID-19 vaccine, T cells, SARS-CoV-2 antibodies, Kidney transplantation, mRNA vaccination.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a transplantace ledvin $x škodlivé účinky $7 D016030
- 650 12
- $a COVID-19 $x imunologie $x prevence a kontrola $7 D000086382
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a vakcíny proti COVID-19 $x imunologie $x aplikace a dávkování $7 D000086663
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a SARS-CoV-2 $x imunologie $7 D000086402
- 650 _2
- $a vakcinace $x metody $7 D014611
- 650 _2
- $a senioři $7 D000368
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Duskova, J
- 700 1_
- $a Mrazova, P
- 700 1_
- $a Fialova, M
- 700 1_
- $a Viklicky, O
- 700 1_
- $a Hruba, P
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 73, č. 4 (2024), s. 655-664
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39264085 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y - $z 0
- 990 __
- $a 20241004 $b ABA008
- 991 __
- $a 20250312151325 $b ABA008
- 999 __
- $a min $b bmc $g 2283511 $s 1229549
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 73 $c 4 $d 655-664 $e 20240831 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
- LZP __
- $a Pubmed-20241004